Medicare beneficiaries who rely on Ozempic or Wegovy will pay sharply less starting in 2027, after the Centers for Medicare and Medicaid Services locked in a negotiated monthly price of $274 for the GLP-1 drugs, down from roughly $959. The price cut, part of the second cycle of Medicare drug price negotiations authorized by the Inflation Reduction Act, covers 15 drugs for cancer and chronic disease and removes one of the largest cost barriers to widely prescribed diabetes and obesity treatments.
Why the $274 GLP-1 price changes the math for millions of Medicare patients
The gap between $959 and $274 per month is not just a line item in federal budgets. For the millions of Part D enrollees managing Type 2 diabetes or obesity, the old price often pushed total out-of-pocket spending past the thresholds where patients skip doses or abandon therapy altogether. A lower negotiated rate, applied across Part D formularies, reduces both plan-level spending and individual copays, which means fewer beneficiaries will hit the catastrophic coverage phase that triggers high cost-sharing.
The practical question is whether cheaper access will prompt doctors to prescribe GLP-1 therapy earlier in a patient’s disease course rather than reserving it as a last resort after older, less effective drugs fail. Commercial insurers still pay close to list price, so Medicare could become the first large-scale test of whether broader, earlier GLP-1 use translates into fewer diabetes-related hospitalizations. No public utilization projections tied to the $274 rate have been released, but the structural incentive is clear: plans that previously restricted these drugs through prior authorization or step-therapy requirements will face less financial pressure to do so.
For individual patients, the impact will be felt in several ways. Lower negotiated prices give Part D plans room to place GLP-1 drugs on more favorable formulary tiers, cutting coinsurance percentages that are calculated off the underlying price. Because Medicare’s out-of-pocket caps and coverage phases are defined in dollar terms, a reduced list price also slows the pace at which patients move through the deductible and initial coverage phases toward higher cost-sharing. Patients who previously hit the catastrophic phase midyear may now stay in lower cost tiers longer, smoothing expenses and making adherence more sustainable.
The negotiated GLP-1 price may also influence how clinicians weigh cost when discussing treatment options with patients. When a once-monthly injection costs nearly $1,000, physicians often hesitate to recommend it to patients on fixed incomes, even if clinical guidelines support its use. At $274, the conversation shifts toward clinical benefit and side-effect profile rather than pure affordability. That dynamic could be especially important for patients with multiple chronic conditions, where preventing complications like cardiovascular events or kidney disease may ultimately reduce overall Medicare spending.
How CMS built the legal and administrative path to the $274 rate
CMS selected Ozempic, Rybelsus, and Wegovy for the second negotiation cycle, known as Initial Price Applicability Year 2027, after federal health officials identified 15 high-spend drugs with no generic competition. The inclusion of multiple GLP-1 products reflected their rapidly growing share of Part D spending and the absence of lower-cost alternatives. By targeting products that account for a disproportionate share of Medicare’s prescription drug budget, CMS aimed to maximize savings while minimizing disruption to the broader market.
The agency has laid out the negotiated figures and supporting documentation on its public program portal, where drug-specific materials detail the Maximum Fair Price for each selected product. For the three Novo Nordisk GLP-1 drugs, CMS posted a dedicated archive explaining how statutory factors-such as clinical benefit, unmet medical need, and R&D costs-fed into the final number. Those files, along with fact sheets and infographics, are designed to give plans, providers, and manufacturers a clear view of how the agency applied its negotiation authority.
To implement the negotiation program, CMS issued a series of policy documents and technical memoranda that were vetted through the federal rulemaking process. The regulatory guidance for the 2027 cycle spells out timelines, data submission requirements, and the methodology for calculating Maximum Fair Prices. The Government Accountability Office reviewed the final IPAY 2027 guidance and classified it as a major rule, confirming that CMS followed required procedural steps and triggering additional congressional notification.
Drug manufacturers, including makers of GLP-1 products, challenged the negotiation framework in multiple federal courts, arguing that the combination of mandatory discounts and civil monetary penalties amounted to unconstitutional coercion. Those challenges advanced quickly to the appellate level, but the Supreme Court declined to intervene, leaving lower-court rulings in place and effectively clearing the final legal obstacle to implementation. With the high court opting not to hear the cases, CMS moved ahead with publishing final prices and instructing Part D sponsors to incorporate them into 2027 bids.
CMS has framed the outcome as a demonstration of statutory authority delivering tangible savings without restricting access. In its public statements on the 15-drug cohort, the agency emphasized that negotiated prices are intended to lower premiums and out-of-pocket costs while maintaining coverage for clinically important therapies. For seniors facing chronic conditions that require lifelong medication, the GLP-1 price cut is both a financial reprieve and an early test of whether Medicare’s new bargaining power can reshape the economics of blockbuster drugs without undermining innovation.
